Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Liquidia’s clinical milestones can feel like navigating a labyrinth of FDA language, trial statistics, and licensing footnotes. Each new Liquidia 8-K material events explained notice might include pivotal updates on YUTREPIA’s path to approval, while a single Form 4 could show an insider buying shares ahead of a data read-out. Our AI-driven platform decodes those complexities so you can focus on what matters, delivering Liquidia SEC filings explained simply the moment they hit EDGAR.
Stop skimming hundred-page PDFs. Stock Titan’s engine extracts the cash-runway tables from every Liquidia quarterly earnings report 10-Q filing, highlights trial spend buried inside the Liquidia annual report 10-K simplified, and flags Liquidia proxy statement executive compensation details side by side with peer data. Need to watch executive moves? Receive Liquidia Form 4 insider transactions real-time alerts that list each Liquidia executive stock transactions Form 4 in context—share price, option type, and historical buying patterns.
Whether you’re comparing treprostinil royalty streams or assessing dilution risk from future capital raises, our coverage spans every filing type—from 10-K, 10-Q, and 8-K to Section 16 reports—updated in seconds. AI-powered summaries, keyword search across historical documents, and exportable tables let you perform rapid Liquidia earnings report filing analysis without specialized training. Use cases include:
- Monitoring Liquidia insider trading Form 4 transactions before trial announcements
- Understanding Liquidia SEC documents with AI for quicker valuation models
- Tracking manufacturing scalability disclosures tied to PRINT® technology
Amendment corrects previously omitted indirect holdings: Dr. Stephen M. Bloch, a director of Liquidia Corp (LQDA), amended a prior Form 4 to include 2,917,169 shares of common stock reported as indirectly held through Canaan VIII L.P. The filing states these shares are held by Canaan LP, whose sole general partner is Canaan Partners VIII LLC; investment and voting decisions are made by the managers of Canaan LLC. The Reporting Person disclaims beneficial ownership except for any pecuniary interest from his LLC interest. No derivative securities are reported in this amendment.
Raman Singh, a director of Liquidia Corp (LQDA), exercised stock options and sold a portion of the resulting shares on 09/15/2025. He exercised a non-qualified option with a $2.51 strike to acquire 25,524 shares and a separate option with a $2.59 strike to acquire 20,000 shares. On the same date he sold 45,524 shares at a volume-weighted average price of $25.81, leaving him with beneficial ownership of 31,255 shares. The filing also discloses 18,396 restricted stock units granted on June 17, 2025 that had not vested as of the report date.
Insider sale notice for LQDA: The filing reports a proposed sale of 45,524 common shares on 09/15/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,175,042.73. The shares were acquired the same day via stock option exercise and paid for in cash. The filing shows 86,091,454 shares outstanding for the issuer. It also discloses a recent sale of 7,500 shares on 09/03/2025 generating $220,650.00 in gross proceeds. The signer certifies no undisclosed material adverse information.
Raman Singh, a director of Liquidia Corporation (LQDA), reported a sale of common stock. The Form 4 shows a transaction dated 09/03/2025 where the reporting person sold 7,500 shares at a price of $29.42 each, leaving 31,255 shares beneficially owned after the sale. The filing notes the total includes 18,396 restricted stock units granted on June 17, 2025 that have not vested as of the Form 4 date. The Form 4 is signed by Raman Singh on 09/05/2025.
Liquidia Corporation (LQDA) filed a Form 144 disclosing a proposed sale of 7,500 common shares with an aggregate market value of $220,650. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 09/03/2025. The securities were acquired as Restricted Stock Units from Liquidia Corporation on 06/16/2025, and the filing reports payment/vesting on that same date. The filing shows 86,091,454 shares outstanding. The form indicates no securities sold by the same person in the past three months. Several standard filer and issuer contact fields in the submitted tables appear blank.
Scott Moomaw, Chief Commercial Officer of Liquidia Corporation (LQDA), reported multiple equity transactions. On 08/29/2025 he received 1,875 restricted stock units (RSUs) that convert one-for-one into common shares, increasing his RSU holdings. On 09/02/2025 he sold a total of 70,692 shares in three transactions: 692 shares at $29.05 and 8,315 plus 61,685 shares at a volume-weighted average price of $28.6224. The Form 4 notes the sales were effected pursuant to Rule 10b5-1 trading plans and some shares were sold to cover taxes related to RSU settlements. Following these transactions he beneficially owned 155,254 common shares (direct).
Russell Schundler, General Counsel of Liquidia Corporation (LQDA), reported multiple transactions in company equity. On 08/29/2025, 2,344 restricted stock units (RSUs) vested and converted into 2,344 shares. On 09/02/2025, 1,063 shares were sold at $29.05 per share under a Rule 10b5-1 plan to cover taxes related to RSU settlement. After these transactions, Schundler beneficially owned 580,098 shares directly and 14,500 shares indirectly (by spouse), for a total of 594,598 shares reported. The filing notes multiple prior RSU grants (2022, 2023, 2024, 2025) with portions unvested and 11,869 shares held under the employee stock purchase plan.
Liquidia Corporation insider Sarah Krepp, Chief Human Resource Officer, reported a small disposition of company common stock under a Rule 10b5-1 trading plan. The Form 4 shows a sale on 08/29/2025 of 209 shares at $29.05 per share, executed pursuant to a 10b5-1 plan adopted December 15, 2023, and the transaction was to cover taxes on RSU settlements. After the sale, Krepp beneficially owns 143,130 shares, including multiple unvested RSU tranches (specified amounts) and 5,312 shares from the 2020 Employee Stock Purchase Plan.
Michael Kaseta, Chief Financial Officer and Chief Operating Officer of Liquidia Corporation (LQDA), reported equity transactions in a Form 4. On 08/29/2025 he had 2,344 restricted stock units (RSUs) convert into common stock, increasing his beneficial ownership to 359,596 shares. Pursuant to a Rule 10b5-1 plan, he sold 1,148 shares on 09/02/2025 at $29.05 per share to cover taxes, leaving 358,448 shares beneficially owned. The filing details prior RSU grants: a 37,500 RSU grant on 01/16/2022 of which 32,813 had vested, multiple grants in 2023–2025 with substantial unvested RSU balances, and 11,257 shares held under the 2020 Employee Stock Purchase Plan.
Liquidia Corp Chief Accounting Officer Dana Boyle reported a transaction under a Rule 10b5-1 plan: on 08/29/2025 she sold 296 shares of common stock at $29.05 per share to cover tax withholding related to vested restricted stock units. Following the sale, Boyle beneficially owns 186,649 shares, which include multiple unvested RSU grants from 2022 through 2025 and 11,869 shares acquired under the 2020 Employee Stock Purchase Plan. The filing is a Form 4 and was signed on 09/03/2025.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
